VectivBio prepping pivotal GI trial with $110M crossover round that could presage IPO

A public listing could be VectivBio’s next financial step now that it has raised $110 million in a crossover round that will fund its planned Phase III trial in short bowel syndrome, as well as possible acquisitions to build its pipeline.

Spun out of Therachon AG last year amid that company’s $340 million acquisition by Pfizer Inc. (NYSE:PFE), VectivBio is developing apraglutide, a GLP-2 analog, to treat short bowel syndrome (SBS), a condition that results from intestinal resection. Patients typically require parenteral support, the IV delivery of essential nutrients, for much of the day...